Bioventus Inc. Class A Common Stock (BVS) is a publicly traded Healthcare sector company. As of July 28, 2026, BVS trades at $12.42 with a market cap of $799.43M and a P/E ratio of 28.55. BVS moved -0.28% today. Year to date, BVS is +67.34%; over the trailing twelve months it is +89.50%. Its 52-week range spans $5.81 to $12.53. Analyst consensus is strong buy with an average price target of $15.00. Rallies surfaces BVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
3 analysts cover BVS: 0 strong buy, 3 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $15.00.
| Metric | Value |
|---|---|
| Price | $12.42 |
| Market Cap | $799.43M |
| P/E Ratio | 28.55 |
| EPS | $0.43 |
| Dividend Yield | 0.61% |
| 52-Week High | $12.53 |
| 52-Week Low | $5.81 |
| Volume | 1.10K |
| Avg Volume | 0 |
| Revenue (TTM) | $576.30M |
| Net Income | $34.54M |
| Gross Margin | 68.69% |
3 analysts cover BVS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.00.